S85041 |
GSK137647A |
源葉(MedMol) | 99% |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.274 ml | 16.372 ml | 32.745 ml |
5 mM | 0.655 ml | 3.274 ml | 6.549 ml |
10 mM | 0.327 ml | 1.637 ml | 3.274 ml |
50 mM | 0.065 ml | 0.327 ml | 0.655 ml |
- 提示:詳情請(qǐng)下載說(shuō)明書。
- 產(chǎn)品描述: GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC50 values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC50 values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response
- 靶點(diǎn): Free Fatty Acid Receptor;GPR
- 體外研究:
GSK137647A (GSK 137647) (50 μM) reduces the production of NO in macrophages without affecting cell viability[1].GSK137647A (GSK 137647) (30 μM; 12 hours) alleviates response to inflammatory stimuli in Caco-2 cells and induces secretion of IL-6[1]. GSK137647A (GSK 137647) (10 μM) reduces the ion flow and affects the colonic epithelial ion transport in healthy. GSK137647A (GSK 137647) (50 μM) increases glucose stimulated insulin secretion. Western Blot Analysis Cell Line: Caco-2 cells Concentration: 30 μM Incubation Time: 12 hours Result: Downregulated FFAR1, FFAR2, and FFAR4 as compared to control. Cell Viability Assay Cell Line: RAW264.7 macrophages Concentration: 10, 20 and 50 μM Incubation Time: 24 hours Result: Without affected cell viability.
- 體內(nèi)研究:
GSK137647A (GSK 137647) (1 mg/kg; i.p.; twice daily, for 7 days; C57BL/6 mice) alleviates colitis in TNBS- and DSS-treated mice. GSK137647A (GSK 137647) (1 mg/kg; i.p.; twice daily, for 7 days; C57BL/6 mice) restores intestinal permeability in vivo. Animal Model: Male C57BL/6 mice Dosage: 1 mg/kg Administration: Intraperitoneal injection; twice daily, for 7 days Result: Had anti-inflammatory effect and reversed colonic injury induced by DSS. Animal Model: Male C57BL/6 mice Dosage: 1 mg/kg Administration: Intraperitoneal injection; twice daily, for 7 days Result: Decreased the amount of FITC and alleviated intestinal epithelial barrier permeability.
- 參考文獻(xiàn):
1. Salaga M, et, al. Activation of Free Fatty Acid Receptor 4 Affects Intestinal Inflammation and Improves Colon Permeability in Mice. Nutrients. 2021 Aug 6;13(8):2716. 2. Sparks SM, et, al. Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120). Bioorg Med Chem Lett. 2014 Jul 15;24(14):3100-3.
- 溶解性: Soluble in DMSO、H2O
- 保存條件: -20℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 3.274 ml 16.372 ml 32.745 ml 5 mM 0.655 ml 3.274 ml 6.549 ml 10 mM 0.327 ml 1.637 ml 3.274 ml 50 mM 0.065 ml 0.327 ml 0.655 ml
- 注意:部分產(chǎn)品我司僅能提供部分信息,我司不保證所提供信息的權(quán)威性,僅供客戶參考交流研究之用。
輸入產(chǎn)品批號(hào):
本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系,公式為:
質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)